查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1806530

微創青光眼手術設備市場：按機制、適應症、手術方法、最終用戶和分銷管道 - 全球預測 2025-2030

Minimally Invasive Glaucoma Surgery Devices Market by Mechanism, Indication, Surgical Approach, End User, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

微創青光眼手術設備市場預計到 2024 年將達到 6.1265 億美元，到 2025 年將達到 6.4708 億美元，到 2030 年將達到 8.578 億美元，複合年成長率為 5.76%。

主要市場統計數據
基準年2024年 6.1265億美元
預計2025年 6.4708億美元
預測年份 2030 8.578億美元
複合年成長率（%） 5.76%

簡要介紹微創青光眼手術設備如何再形成整個護理領域的臨床決策和程序路徑

微創青光眼手術器械正在重新定義青光眼治療途徑，它提供了更具破壞性的手術替代方案，並專注於安全性、快速恢復和在臨床實踐中的可重複應用。近期器械創新和外科醫生不斷變化的偏好正在加速對治療流程的重新評估，並吸引了眼科領域領導者、門診手術醫生和臨床創新者的注意。本介紹闡述了技術進步、臨床證據的累積以及醫療服務模式的不斷發展如何共同塑造青光眼的採用軌跡和商業性重點。

不斷發展的設備設計、護理地點的變化和付款人的期望如何融合，改寫競爭動態和臨床決策路徑

在技​​術進步、臨床證據日益增多以及醫療機構運作模式革新的推動下，微創青光眼手術設備領域正在經歷變革。設備的演進已超越單點改進，需要從系統層面重新思考如何實現壓力調節、如何輸送設備以及如何衡量療效，這迫使臨床醫生和管理人員重新評估治療順序和治療路徑。

對 2025 年美國關稅如何重塑整個醫療設備價值鏈的供應鏈、籌資策略和商業合約進行定性評估

美國於2025年宣布的關稅政策環境，對微創青光眼手術器械生態系統的參與者產生了重大的業務和策略影響。雖然關稅通常被視為貿易政策槓桿，但其累積效應已波及供應鏈、籌資策略和商業性定價。擁有全球化採購足跡的製造商必須重新評估其供應商組合，以維持利潤率並確保零件的持續供應。

細分主導的見解，解釋機制、臨床適應症、手術方法、醫療環境和分銷動態如何決定採用和定位

細分市場層面的動態變化揭示了機制、適應症、手術方法、最終用戶和分銷管道如何各自塑造出製造商和醫療保健提供者必須應對的競爭和臨床路徑。在小梁微繞道手術中，Hydrus Microstent、Istent、Kahook Dual Blade 和 Trabectome 等特定器械的變體展現了設計差異化如何影響植入技術和術後管理，因為能夠最大程度減少組織損傷並縮短手術時間的器械更容易在門診環境中應用。

美洲、中東和非洲以及亞太地區的監管影響、商業化和臨床醫生採用

區域動態正在重塑不同地區的投資重點、監管參與度和商業性執行，每個地區都呈現出獨特的機會和限制。在美洲，創新中心、集中的付款人互動以及高密度的門診手術中心營造出一種有利於療效可預測且可透過現有分銷網路進行擴展的設備的環境。該地區的監管途徑和報銷談判通常會獎勵可靠的臨床證據和基於價值的敘述。

從現有的投資組合到新興企業主導的顛覆，不同的企業策略如何影響商業化、證據產生和競爭定位

公司層級的策略展現出各種行為，這些行為反映了風險偏好、資源頻寬和策略重點的差異。許多現有的醫療設備公司專注於逐步增強其設備，擴展外科醫生培訓項目，並利用現有銷售管道推動其在門診和住院環境中的應用。這些現有公司通常強調產品組合整合、捆綁圍手術全期服務以及支付方參與，以將醫療設備嵌入到護理路徑中。

製造商、供應鏈領導者、臨床醫生和付款人可以部署實用的策略槓桿來促進採用並保護他們的營運免受政策和市場衝擊。

對於尋求將洞察轉化為臨床應用、商業性吸引力和業務韌性方面可衡量成果的領導者來說，可行的優先事項已經浮現。製造商應優先建立模組化證據包，以同時滿足臨床終點和付款人相關的價值指標，同時設計培訓課程，以縮短外科醫生的學習曲線並促進門診患者採用。對上市後監測和真實世界證據平台的投資將有助於增強報銷論點並維護供應商的信心。

嚴格的多資訊來源調查方法，結合主要臨床訪談、監管審查和重複檢驗，確保分析的可靠性

本分析所採用的調查方法是綜合三個證據線索，這些證據線索來自主要相關人員研究、針對性的二次研究和系統性檢驗方案。主要輸入包括對外科醫生、手術室經理、採購主管和設備開發人員進行結構化訪談，旨在揭示他們在工作中對設備選擇、手術物流和報銷動態的見解。這些訪談也輔以手術工作流程和訓練課程的觀察，以捕捉已發表文獻中可能未提及的實際整合挑戰。

整合強調臨床相關性、供應鏈彈性和有針對性的證據產生的策略要點，以確保長期採用

本執行摘要概述了定義微創青光眼手術器械的策略輪廓：跨機制的技術多樣化、跨適應症和手術方法的臨床應用的不斷發展，以及本地化商業化策略日益重要。相關人員若能將產品設計與臨床醫師的實際需求結合，投資於以結果為導向的證據，並建立具有韌性和靈活性的供應鏈，則最有可能獲得持久的價值。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章市場動態

  • 用於治療青光眼的白內障和腹膜內 MIGS 聯合手術的快速增加正在簡化手術工作流程
  • 無需每日眼藥水即永續控制眼壓的藥物釋放型上腔微型支架的商業化
  • 小梁旁路支架因其簡單性和在早期青光眼中的良好安全性而越來越受到外科醫生的認可
  • 增加對智慧術中影像整合的投資，以提高 MIGS 設備放置的準確性和手術結果
  • 擴大門診 MIGS 治療的報銷範圍，改善主要已開發市場患者的治療可近性
  • 開發下一代生物可吸收植入以減少異物反應和長期組織疤痕
  • 評估 MIGS 裝置與緩釋性藥物聯合治療以提高療效的臨床試驗激增
  • 新興市場製造商正在提供具有成本競爭力的 MIGS 替代品，給現有製造商帶來越來越大的價格壓力。

第6章 市場洞察

  • 波特五力分析
  • PESTEL分析

第7章 2025年美國關稅的累積影響

第8章 微創青光眼手術設備市場（依機轉）

  • 結膜下濾過
  • 脈絡膜上腔分流術
  • 小梁微旁路術
    • Hydrus 微型支架
    • IStent
    • Kahook 雙刃刀
    • 小梁切除術

9. 微創青光眼手術設備市場（按適應症）

  • 兒童青光眼
  • 原發性開放性青光眼
  • 續發性青光眼

10. 微創青光眼手術設備市場（依手術方法）

  • 阿貝克斯特諾
  • 國際

第 11 章微創青光眼手術設備市場（按最終用戶）

  • 門診手術中心
  • 醫院
  • 眼科診所

第 12 章微創青光眼手術設備市場（按通路）

  • 離線
  • 線上

13.美洲微創青光眼手術設備市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

14. 歐洲、中東和非洲微創青光眼手術設備市場

  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 阿拉伯聯合大公國
  • 沙烏地阿拉伯
  • 南非
  • 丹麥
  • 荷蘭
  • 卡達
  • 芬蘭
  • 瑞典
  • 奈及利亞
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波蘭
  • 瑞士

15. 亞太地區微創青光眼手術設備市場

  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • 印尼
  • 泰國
  • 菲律賓
  • 馬來西亞
  • 新加坡
  • 越南
  • 台灣

第16章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Alcon Inc.
    • Ellex Medical Lasers Ltd.
    • AbbVie Inc.
    • Bausch+Lomb France SAS
    • Carl-Zeiss AG
    • Corza Ophthalmology
    • Glaukos Corporation
    • I Optima Ltd.
    • Iridex Corporation
    • iSTAR Medical
    • Johnson & Johnson Vision Care, Inc.
    • Lumenis Be Ltd.
    • New World Medical, Inc.
    • Optonol Ltd.
    • Santen Pharmaceutical Co., Ltd.
    • Sight Sciences, Inc.
    • Ziemer Ophthalmic Systems AG

第17章 研究人工智慧

第18章 研究統計

第19章 研究聯絡人

第20章 研究報導

第21章 附錄

Product Code: MRR-036C5CF3A869

The Minimally Invasive Glaucoma Surgery Devices Market was valued at USD 612.65 million in 2024 and is projected to grow to USD 647.08 million in 2025, with a CAGR of 5.76%, reaching USD 857.80 million by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 612.65 million
Estimated Year [2025] USD 647.08 million
Forecast Year [2030] USD 857.80 million
CAGR (%) 5.76%

A concise orientation to how minimally invasive glaucoma surgery devices are reshaping clinical decision-making and procedural pathways across care settings

Minimally invasive glaucoma surgery devices are redefining therapeutic pathways for glaucoma by offering less disruptive surgical alternatives that emphasize safety, faster recovery, and iterative adoption across clinical settings. Recent device innovations and evolving surgeon preferences have accelerated the re-evaluation of care algorithms, driving attention from ophthalmic leaders, ambulatory operators, and clinical innovators. This introduction frames the convergence of technological refinement, clinical evidence development, and evolving delivery models that together shape adoption trajectories and commercial priorities.

The clinical impetus for minimally invasive approaches stems from the demand to reduce reliance on chronic topical therapies, mitigate procedural risk, and expand treatment options earlier in disease pathways. As techniques have matured, stakeholders have responded by reconfiguring surgical workflows, redefining training pathways, and integrating multidisciplinary teams to manage perioperative care. Consequently, decision makers must balance device selection, surgeon training, and facility readiness alongside reimbursement realities and patient expectations.

Transitioning from procedural innovation to broader adoption requires clarity on comparative performance, ease of integration, and real-world outcomes. This introduction sets the stage for a comprehensive examination of how mechanism, indication, surgical approach, end user, and distribution dynamics influence strategic choices across manufacturers, healthcare systems, and clinical practices.

How evolving device designs, site-of-care migration, and payer expectations are converging to rewrite competitive dynamics and clinical decision pathways

The landscape for minimally invasive glaucoma surgery devices is undergoing transformative shifts driven by technological refinement, clinical evidence accumulation, and operational redesign across care sites. Device evolution has moved beyond single-point improvements to a systems-level rethinking of how pressure modulation is achieved, how devices are delivered, and how outcomes are measured, thereby prompting clinicians and administrators to reassess treatment sequencing and care pathways.

Concurrently, the locus of care is shifting as ambulatory surgery centers scale procedures that were once hospital-bound, while ophthalmic clinics expand pre- and post-operative management capabilities. This redistribution of procedure volume is supported by streamlined device profiles that reduce intraoperative complexity and postoperative follow-up demands. Alongside clinical adoption, payer dialogues have evolved to focus on value, total cost of care, and patient-reported outcomes, increasing pressure on manufacturers to demonstrate tangible improvements in safety and quality metrics.

Moreover, innovation ecosystems have broadened: partnerships between device developers, surgical training organizations, and digital-health platforms are enabling faster surgeon onboarding and outcome tracking. In parallel, a more fragmented supplier base, including nimble startups and strategic alliances with established medical device companies, is intensifying competition and accelerating feature differentiation. Together, these forces are redefining competitive advantage in a market where clinical relevance, commercial scalability, and the ability to demonstrate value to payers and providers determine long-term success.

Qualitative assessment of how the 2025 United States tariff measures reshaped supply chains, sourcing strategies, and commercial contracting across the device value chain

The policy environment introduced by United States tariffs announced in 2025 has created a material set of operational and strategic implications for participants in the minimally invasive glaucoma surgery device ecosystem. While tariffs are typically characterized as trade policy levers, their cumulative effect has rippled across supply chains, sourcing strategies, and commercial pricing decisions. Manufacturers with globalized procurement footprints have had to reassess supplier portfolios to preserve margin and ensure continuity of component availability.

Faced with increased input costs and potential delays, many device developers accelerated efforts to diversify their supplier base and identify near-shore or onshore manufacturing alternatives. This transition, however, involves lead times for qualification, regulatory transfer activities, and capital allocation decisions that can affect product timelines. For downstream stakeholders such as distributors and health systems, the tariff-driven adjustments manifested as shifts in negotiated pricing and inventory management tactics, including higher buffer stocks for critical implants and consumables.

Importantly, tariffs also influenced strategic route-to-market choices. Some manufacturers prioritized direct distribution in key regions to control margin erosion and pricing signaling, while others intensified collaboration with regional partners to mitigate tariff exposure. For clinicians and patients, the practical consequences have been uneven across settings: ambulatory centers and clinics operating on tighter procurement cycles felt pricing pressure earlier, while hospitals with longer contracting horizons absorbed changes more gradually. Overall, the 2025 tariffs catalyzed a reassessment of supply chain resilience, manufacturing location strategy, and commercial contracting practices across the value chain.

Segment-driven insights explaining how mechanism, clinical indication, surgical approach, care setting, and distribution dynamics determine adoption and positioning

Segment-level dynamics reveal how mechanism, indication, surgical approach, end user, and distribution channel each create distinct competitive and clinical pathways that manufacturers and providers must navigate. Based on Mechanism, the market is studied across Subconjunctival Filtration, Suprachoroidal Shunts, and Trabecular Micro-Bypass; within Trabecular Micro-Bypass, specific device variations such as Hydrus Microstent, IStent, Kahook Dual Blade, and Trabectome illustrate how design differentiation affects implantation technique and postoperative management. This mechanistic granularity helps explain divergent adoption curves, since devices that minimize tissue disruption and shorten operative times are more readily integrated into ambulatory settings.

Based on Indication, the market is studied across Pediatric Glaucoma, Primary Open Angle Glaucoma, and Secondary Glaucoma, and these clinical subpopulations demand distinct evidence packages and training approaches. Pediatric indications require long-term safety data and specialized instrumentation, whereas primary open angle glaucoma presentations prioritize combination therapy strategies and minimally disruptive options for earlier intervention. Secondary glaucoma cases often necessitate tailored solutions that address complex anatomy or prior surgical history, influencing device selection and surgeon preference.

Based on Surgical Approach, the market is studied across Ab Externo and Ab Interno, with the latter gaining traction due to reduced invasiveness and faster patient recovery, while ab externo techniques remain relevant for certain anatomical contexts. Based on End User, the market is studied across Ambulatory Surgery Centers, Hospital, and Ophthalmic Clinics, each with different procurement cycles, staffing models, and reimbursement frameworks that shape product positioning. Based on Distribution Channel, the market is studied across Offline and Online pathways, where digital platforms are increasingly important for clinician education, device ordering, and aftermarket support. Together, these segmentation lenses provide a multidimensional view of strategic priorities and practical constraints for product development, commercialization, and clinical adoption.

Regional implications for regulatory engagement, commercialization, and clinician adoption across Americas, Europe Middle East & Africa, and Asia-Pacific geographies

Regional dynamics are reshaping investment priorities, regulatory engagement, and commercial execution across distinct geographies, each presenting unique opportunities and constraints. In the Americas, innovation hubs, concentrated payer dialogues, and a high density of ambulatory surgery centers create an environment that favors devices which deliver predictable outcomes and can be scaled through established distribution networks. Regulatory pathways and reimbursement negotiations in this region often reward robust clinical evidence and value-based narratives.

In Europe, Middle East & Africa, fragmentation of regulatory regimes and heterogeneity in hospital procurement models require adaptive commercialization strategies. Manufacturers operating in this region benefit from modular clinical programs that can address varying evidence thresholds and from partnerships that support localized training and post-market surveillance. Price sensitivity in many markets coexists with centers of clinical excellence that serve as influential early adopters.

In Asia-Pacific, rapid capacity expansion in specialty ophthalmic centers, evolving reimbursement frameworks, and a large patient base drive diverse adoption scenarios. Local manufacturing and strategic licensing partnerships are prominent approaches to address regulatory nuances and cost expectations. Moreover, regional centers often become focal points for clinical trials and training initiatives that support broader commercialization across neighboring markets. Taken together, regional nuances demand tailored regulatory, clinical, and commercial roadmaps to optimize product uptake and long-term sustainability.

How varied company strategies - from incumbent portfolio plays to startup-led disruption - shape commercialization, evidence generation, and competitive positioning

Company-level strategies reveal a spectrum of behaviors that reflect differing risk appetites, resource endowments, and strategic priorities. Many established medical device firms focus on incremental device enhancements, scaling surgeon training programs, and leveraging existing sales channels to accelerate penetration in ambulatory and hospital settings. These incumbents often emphasize portfolio integration, bundling of perioperative services, and payer engagement to embed devices within care pathways.

Simultaneously, innovative smaller firms and startups are concentrating on disruptive device concepts, differentiated delivery mechanisms, and targeted clinical evidence to enter niche indications or surgical subsegments. These innovators frequently adopt agile development cycles, collaborate with specialized surgical centers for early feasibility studies, and pursue targeted regulatory strategies to expedite market entry. Strategic partnerships between larger firms and these innovators are increasingly common, enabling faster commercialization of novel technologies while mitigating development risk.

Across the competitive spectrum, companies prioritize three interlocking capabilities: clinical evidence generation that aligns with payer value metrics, scalable distribution and training models that lower adoption friction, and supply chain resilience that minimizes exposure to geopolitical shifts. Organizations that excel across these dimensions tend to be those that invest early in robust post-market data collection, cultivate strong clinician champions, and design commercial models that reflect the procedural economics of ambulatory and hospital environments.

Practical strategic moves manufacturers, supply chain leaders, clinicians, and payers can deploy to accelerate adoption and insulate operations from policy and market shocks

Actionable priorities emerge for leaders seeking to convert insights into measurable outcomes in clinical adoption, commercial traction, and operational resilience. Manufacturers should prioritize building modular evidence packages that address both clinical endpoints and payer-relevant value metrics, while simultaneously designing training curricula that reduce surgeon learning curves and facilitate uptake in ambulatory settings. Investment in post-market surveillance and real-world evidence platforms will help strengthen reimbursement arguments and maintain provider confidence.

Supply chain leaders must accelerate dual-sourcing strategies and evaluate near-shore manufacturing options to reduce exposure to tariff-induced cost shocks and logistics disruptions. Contracting teams should renegotiate terms with an eye to flexibility, incorporating volume-based tiers and shorter re-pricing windows to respond to rapid policy shifts. For distributors and health systems, aligning procurement cadence with device lifecycle stages and developing contingency inventory plans will preserve access and protect patient scheduling.

Clinician leaders and hospital administrators should collaborate to define clear patient selection criteria, standardize perioperative care pathways, and measure patient-reported outcomes to demonstrate comparative value. Finally, cross-sector stakeholders are advised to pursue targeted pilot programs that combine device deployment with economic modeling and outcomes tracking to catalyze payer discussions and build local evidence for broader adoption.

A rigorous, multi-source research approach combining primary clinical interviews, regulatory review, and iterative validation to ensure analytical reliability

The research methodology underpinning this analysis integrates triangulated evidence drawn from primary stakeholder engagement, targeted secondary review, and systematic validation protocols. Primary inputs included structured interviews with surgeons, operating room managers, procurement leaders, and device developers, designed to surface on-the-ground insights about device selection, procedural logistics, and reimbursement dynamics. These interviews were complemented by observational inputs from procedure workflows and training sessions to capture practical integration challenges that may not be visible in published literature.

Secondary research encompassed regulatory documentation, peer-reviewed clinical literature, and public filings to map device approvals, indications, and clinical endpoints. Where regulatory documents were limited, corroborative interviews and procedural observations helped contextualize approval timelines and post-market obligations. Data synthesis involved cross-referencing clinical outcomes with distribution patterns and procurement practices to identify consistent trends and outliers.

Quality assurance was maintained through iterative review cycles with domain experts, triangulation across independent sources, and a clear statement of limitations where data gaps exist. The methodology emphasizes transparency in provenance and reproducibility of analytical steps, and notes that while effort was made to incorporate a diverse set of perspectives, local regulatory idiosyncrasies and proprietary commercial arrangements may require supplemental, context-specific investigation for transactional decisions.

Synthesis of strategic imperatives emphasizing clinical relevance, supply chain resilience, and targeted evidence generation to secure long-term adoption

This executive summary synthesizes the strategic contours that now define minimally invasive glaucoma surgery devices: technological diversification across mechanisms, evolving clinical adoption across indications and surgical approaches, and the increasing importance of regionalized commercialization strategies. Stakeholders that align product design with pragmatic clinician needs, invest in outcome-focused evidence, and build resilient, flexible supply chains are best positioned to capture durable value.

The cumulative policy and market shifts of recent years have underscored the need for agility. Providers and manufacturers must continuously reassess operating assumptions in light of tariff exposure, shifting site-of-care economics, and payer expectations for demonstrated value. Importantly, the most successful strategies will integrate clinical, commercial, and operational levers-pairing device differentiation with scalable training, targeted evidence generation, and adaptive contracting.

Looking forward, the interplay between clinical innovation and distribution innovation will determine which technologies become standard of care and which remain niche. Companies and health systems that invest early in collaborative pilots, robust real-world evidence programs, and surgeon enablement will create the conditions for sustained adoption and improved patient outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Rapid rise in combined cataract and ab interno MIGS procedures for glaucoma management leading to streamlined surgical workflows
  • 5.2. Commercial launch of drug-eluting suprachoroidal microstents offering sustained intraocular pressure control without daily drops
  • 5.3. Growing surgeon preference for trabecular meshwork bypass stents driven by simplicity and favorable safety profile in early glaucoma
  • 5.4. Increasing investment in smart intraoperative imaging integration to enhance precision of MIGS device placement and procedural outcomes
  • 5.5. Expansion of reimbursement coverage for office-based MIGS treatments improving patient access in key developed markets
  • 5.6. Development of next-generation bioresorbable implants aimed at reducing foreign body reactions and long-term tissue scarring
  • 5.7. Surge in clinical trials evaluating combination therapies of MIGS devices with sustained-release pharmacologics for enhanced efficacy
  • 5.8. Entry of emerging-market manufacturers offering cost-competitive MIGS alternatives spurring pricing pressure on established players

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Minimally Invasive Glaucoma Surgery Devices Market, by Mechanism

  • 8.1. Introduction
  • 8.2. Subconjunctival Filtration
  • 8.3. Suprachoroidal Shunts
  • 8.4. Trabecular Micro-Bypass
    • 8.4.1. Hydrus Microstent
    • 8.4.2. IStent
    • 8.4.3. Kahook Dual Blade
    • 8.4.4. Trabectome

9. Minimally Invasive Glaucoma Surgery Devices Market, by Indication

  • 9.1. Introduction
  • 9.2. Pediatric Glaucoma
  • 9.3. Primary Open Angle Glaucoma
  • 9.4. Secondary Glaucoma

10. Minimally Invasive Glaucoma Surgery Devices Market, by Surgical Approach

  • 10.1. Introduction
  • 10.2. Ab Externo
  • 10.3. Ab Interno

11. Minimally Invasive Glaucoma Surgery Devices Market, by End User

  • 11.1. Introduction
  • 11.2. Ambulatory Surgery Centers
  • 11.3. Hospital
  • 11.4. Ophthalmic Clinics

12. Minimally Invasive Glaucoma Surgery Devices Market, by Distribution Channel

  • 12.1. Introduction
  • 12.2. Offline
  • 12.3. Online

13. Americas Minimally Invasive Glaucoma Surgery Devices Market

  • 13.1. Introduction
  • 13.2. United States
  • 13.3. Canada
  • 13.4. Mexico
  • 13.5. Brazil
  • 13.6. Argentina

14. Europe, Middle East & Africa Minimally Invasive Glaucoma Surgery Devices Market

  • 14.1. Introduction
  • 14.2. United Kingdom
  • 14.3. Germany
  • 14.4. France
  • 14.5. Russia
  • 14.6. Italy
  • 14.7. Spain
  • 14.8. United Arab Emirates
  • 14.9. Saudi Arabia
  • 14.10. South Africa
  • 14.11. Denmark
  • 14.12. Netherlands
  • 14.13. Qatar
  • 14.14. Finland
  • 14.15. Sweden
  • 14.16. Nigeria
  • 14.17. Egypt
  • 14.18. Turkey
  • 14.19. Israel
  • 14.20. Norway
  • 14.21. Poland
  • 14.22. Switzerland

15. Asia-Pacific Minimally Invasive Glaucoma Surgery Devices Market

  • 15.1. Introduction
  • 15.2. China
  • 15.3. India
  • 15.4. Japan
  • 15.5. Australia
  • 15.6. South Korea
  • 15.7. Indonesia
  • 15.8. Thailand
  • 15.9. Philippines
  • 15.10. Malaysia
  • 15.11. Singapore
  • 15.12. Vietnam
  • 15.13. Taiwan

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Alcon Inc.
    • 16.3.2. Ellex Medical Lasers Ltd.
    • 16.3.3. AbbVie Inc.
    • 16.3.4. Bausch+Lomb France SAS
    • 16.3.5. Carl-Zeiss AG
    • 16.3.6. Corza Ophthalmology
    • 16.3.7. Glaukos Corporation
    • 16.3.8. I Optima Ltd.
    • 16.3.9. Iridex Corporation
    • 16.3.10. iSTAR Medical
    • 16.3.11. Johnson & Johnson Vision Care, Inc.
    • 16.3.12. Lumenis Be Ltd.
    • 16.3.13. New World Medical, Inc.
    • 16.3.14. Optonol Ltd.
    • 16.3.15. Santen Pharmaceutical Co., Ltd.
    • 16.3.16. Sight Sciences, Inc.
    • 16.3.17. Ziemer Ophthalmic Systems AG

17. ResearchAI

18. ResearchStatistics

19. ResearchContacts

20. ResearchArticles

21. Appendix

LIST OF FIGURES

  • FIGURE 1. MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 16. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 18. UNITED STATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 24. MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 25. MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET: RESEARCHAI
  • FIGURE 26. MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET: RESEARCHSTATISTICS
  • FIGURE 27. MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET: RESEARCHCONTACTS
  • FIGURE 28. MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUBCONJUNCTIVAL FILTRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUBCONJUNCTIVAL FILTRATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUPRACHOROIDAL SHUNTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUPRACHOROIDAL SHUNTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY HYDRUS MICROSTENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY HYDRUS MICROSTENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY ISTENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY ISTENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY KAHOOK DUAL BLADE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY KAHOOK DUAL BLADE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECTOME, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECTOME, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY PEDIATRIC GLAUCOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY PEDIATRIC GLAUCOMA, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY PRIMARY OPEN ANGLE GLAUCOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY PRIMARY OPEN ANGLE GLAUCOMA, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SECONDARY GLAUCOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SECONDARY GLAUCOMA, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY AB EXTERNO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY AB EXTERNO, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY AB INTERNO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY AB INTERNO, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY OPHTHALMIC CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY OPHTHALMIC CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY OFFLINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY ONLINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 56. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
  • TABLE 57. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2018-2024 (USD MILLION)
  • TABLE 58. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2025-2030 (USD MILLION)
  • TABLE 59. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 60. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 61. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2018-2024 (USD MILLION)
  • TABLE 62. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2025-2030 (USD MILLION)
  • TABLE 63. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 64. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 65. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 66. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 67. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 69. UNITED STATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 70. UNITED STATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
  • TABLE 71. UNITED STATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2018-2024 (USD MILLION)
  • TABLE 72. UNITED STATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2025-2030 (USD MILLION)
  • TABLE 73. UNITED STATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 74. UNITED STATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 75. UNITED STATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2018-2024 (USD MILLION)
  • TABLE 76. UNITED STATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2025-2030 (USD MILLION)
  • TABLE 77. UNITED STATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 78. UNITED STATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 79. UNITED STATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 80. UNITED STATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 81. UNITED STATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 82. UNITED STATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 83. CANADA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 84. CANADA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
  • TABLE 85. CANADA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2018-2024 (USD MILLION)
  • TABLE 86. CANADA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2025-2030 (USD MILLION)
  • TABLE 87. CANADA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 88. CANADA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 89. CANADA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2018-2024 (USD MILLION)
  • TABLE 90. CANADA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2025-2030 (USD MILLION)
  • TABLE 91. CANADA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 92. CANADA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 93. CANADA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 94. CANADA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 95. MEXICO MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 96. MEXICO MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
  • TABLE 97. MEXICO MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2018-2024 (USD MILLION)
  • TABLE 98. MEXICO MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2025-2030 (USD MILLION)
  • TABLE 99. MEXICO MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 100. MEXICO MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 101. MEXICO MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2018-2024 (USD MILLION)
  • TABLE 102. MEXICO MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2025-2030 (USD MILLION)
  • TABLE 103. MEXICO MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 104. MEXICO MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 105. MEXICO MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 106. MEXICO MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 107. BRAZIL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 108. BRAZIL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
  • TABLE 109. BRAZIL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2018-2024 (USD MILLION)
  • TABLE 110. BRAZIL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2025-2030 (USD MILLION)
  • TABLE 111. BRAZIL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 112. BRAZIL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 113. BRAZIL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2018-2024 (USD MILLION)
  • TABLE 114. BRAZIL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2025-2030 (USD MILLION)
  • TABLE 115. BRAZIL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 116. BRAZIL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 117. BRAZIL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 118. BRAZIL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 119. ARGENTINA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 120. ARGENTINA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
  • TABLE 121. ARGENTINA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2018-2024 (USD MILLION)
  • TABLE 122. ARGENTINA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2025-2030 (USD MILLION)
  • TABLE 123. ARGENTINA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 124. ARGENTINA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 125. ARGENTINA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2018-2024 (USD MILLION)
  • TABLE 126. ARGENTINA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2025-2030 (USD MILLION)
  • TABLE 127. ARGENTINA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 128. ARGENTINA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 129. ARGENTINA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 130. ARGENTINA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2018-2024 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2025-2030 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2018-2024 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2025-2030 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 146. UNITED KINGDOM MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2018-2024 (USD MILLION)
  • TABLE 148. UNITED KINGDOM MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2025-2030 (USD MILLION)
  • TABLE 149. UNITED KINGDOM MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 150. UNITED KINGDOM MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 151. UNITED KINGDOM MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2018-2024 (USD MILLION)
  • TABLE 152. UNITED KINGDOM MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2025-2030 (USD MILLION)
  • TABLE 153. UNITED KINGDOM MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 154. UNITED KINGDOM MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 155. UNITED KINGDOM MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 156. UNITED KINGDOM MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 157. GERMANY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 158. GERMANY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
  • TABLE 159. GERMANY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2018-2024 (USD MILLION)
  • TABLE 160. GERMANY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2025-2030 (USD MILLION)
  • TABLE 161. GERMANY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 162. GERMANY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 163. GERMANY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2018-2024 (USD MILLION)
  • TABLE 164. GERMANY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2025-2030 (USD MILLION)
  • TABLE 165. GERMANY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 166. GERMANY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 167. GERMANY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 168. GERMANY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 169. FRANCE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 170. FRANCE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
  • TABLE 171. FRANCE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2018-2024 (USD MILLION)
  • TABLE 172. FRANCE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2025-2030 (USD MILLION)
  • TABLE 173. FRANCE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 174. FRANCE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 175. FRANCE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2018-2024 (USD MILLION)
  • TABLE 176. FRANCE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2025-2030 (USD MILLION)
  • TABLE 177. FRANCE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 178. FRANCE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 179. FRANCE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 180. FRANCE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 181. RUSSIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 182. RUSSIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
  • TABLE 183. RUSSIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2018-2024 (USD MILLION)
  • TABLE 184. RUSSIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2025-2030 (USD MILLION)
  • TABLE 185. RUSSIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 186. RUSSIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 187. RUSSIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2018-2024 (USD MILLION)
  • TABLE 188. RUSSIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2025-2030 (USD MILLION)
  • TABLE 189. RUSSIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 190. RUSSIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 191. RUSSIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 192. RUSSIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 193. ITALY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 194. ITALY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
  • TABLE 195. ITALY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2018-2024 (USD MILLION)
  • TABLE 196. ITALY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2025-2030 (USD MILLION)
  • TABLE 197. ITALY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 198. ITALY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 199. ITALY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2018-2024 (USD MILLION)
  • TABLE 200. ITALY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2025-2030 (USD MILLION)
  • TABLE 201. ITALY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. ITALY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 203. ITALY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 204. ITALY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 205. SPAIN MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 206. SPAIN MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
  • TABLE 207. SPAIN MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2018-2024 (USD MILLION)
  • TABLE 208. SPAIN MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2025-2030 (USD MILLION)
  • TABLE 209. SPAIN MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 210. SPAIN MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 211. SPAIN MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2018-2024 (USD MILLION)
  • TABLE 212. SPAIN MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2025-2030 (USD MILLION)
  • TABLE 213. SPAIN MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 214. SPAIN MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 215. SPAIN MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 216. SPAIN MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 217. UNITED ARAB EMIRATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 218. UNITED ARAB EMIRATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
  • TABLE 219. UNITED ARAB EMIRATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2018-2024 (USD MILLION)
  • TABLE 220. UNITED ARAB EMIRATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2025-2030 (USD MILLION)
  • TABLE 221. UNITED ARAB EMIRATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 222. UNITED ARAB EMIRATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 223. UNITED ARAB EMIRATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2018-2024 (USD MILLION)
  • TABLE 224. UNITED ARAB EMIRATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2025-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 229. SAUDI ARABIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 230. SAUDI ARABIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
  • TABLE 231. SAUDI ARABIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2018-2024 (USD MILLION)
  • TABLE 232. SAUDI ARABIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2025-2030 (USD MILLION)
  • TABLE 233. SAUDI ARABIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 234. SAUDI ARABIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 235. SAUDI ARABIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2018-2024 (USD MILLION)
  • TABLE 236. SAUDI ARABIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2025-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 238. SAUDI ARABIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 240. SAUDI ARABIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 241. SOUTH AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 242. SOUTH AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2018-2024 (USD MILLION)
  • TABLE 244. SOUTH AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2025-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 246. SOUTH AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 247. SOUTH AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2018-2024 (USD MILLION)
  • TABLE 248. SOUTH AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2025-2030 (USD MILLION)
  • TABLE 249. SOUTH AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. SOUTH AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 251. SOUTH AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 252. SOUTH AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 253. DENMARK MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 254. DENMARK MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
  • TABLE 255. DENMARK MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2018-2024 (USD MILLION)
  • TABLE 256. DENMARK MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2025-2030 (USD MILLION)
  • TABLE 257. DENMARK MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 258. DENMARK MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 259. DENMARK MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2018-2024 (USD MILLION)
  • TABLE 260. DENMARK MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2025-2030 (USD MILLION)
  • TABLE 261. DENMARK MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 262. DENMARK MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 263. DENMARK MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 264. DENMARK MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 265. NETHERLANDS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 266. NETHERLANDS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2018-2024 (USD MILLION)
  • TABLE 268. NETHERLANDS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2025-2030 (USD MILLION)

TABLE 26